DK0941344T3 - Humaniserede anti-CD11a-antistoffer - Google Patents

Humaniserede anti-CD11a-antistoffer

Info

Publication number
DK0941344T3
DK0941344T3 DK97912841T DK97912841T DK0941344T3 DK 0941344 T3 DK0941344 T3 DK 0941344T3 DK 97912841 T DK97912841 T DK 97912841T DK 97912841 T DK97912841 T DK 97912841T DK 0941344 T3 DK0941344 T3 DK 0941344T3
Authority
DK
Denmark
Prior art keywords
humanized anti
cd11a antibodies
cd11a
antibodies
humanized
Prior art date
Application number
DK97912841T
Other languages
Danish (da)
English (en)
Inventor
Paula M Jardieu
Leonard G Presta
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK0941344T3 publication Critical patent/DK0941344T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK97912841T 1996-11-27 1997-10-20 Humaniserede anti-CD11a-antistoffer DK0941344T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75720596A 1996-11-27 1996-11-27

Publications (1)

Publication Number Publication Date
DK0941344T3 true DK0941344T3 (da) 2004-09-27

Family

ID=25046834

Family Applications (2)

Application Number Title Priority Date Filing Date
DK97912841T DK0941344T3 (da) 1996-11-27 1997-10-20 Humaniserede anti-CD11a-antistoffer
DK04004941.3T DK1516629T3 (da) 1996-11-27 1997-10-20 Humaniseret anti-CD-11a antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK04004941.3T DK1516629T3 (da) 1996-11-27 1997-10-20 Humaniseret anti-CD-11a antibodies

Country Status (17)

Country Link
EP (2) EP0941344B1 (cs)
JP (2) JP3778945B2 (cs)
KR (1) KR100532178B1 (cs)
AR (1) AR008919A1 (cs)
AT (1) ATE267257T1 (cs)
AU (1) AU731817C (cs)
CA (1) CA2272842C (cs)
DE (3) DE122004000047I1 (cs)
DK (2) DK0941344T3 (cs)
ES (1) ES2221045T3 (cs)
FR (1) FR04C0028I2 (cs)
IL (3) IL130143A0 (cs)
LU (1) LU91122I2 (cs)
NL (1) NL300163I2 (cs)
PT (1) PT941344E (cs)
WO (1) WO1998023761A1 (cs)
ZA (1) ZA979599B (cs)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
EP1950300A3 (en) 1998-11-18 2011-03-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
US6632926B1 (en) 1998-11-18 2003-10-14 Genentech, Inc. Antibody variants
DE60042735D1 (de) * 1999-03-19 2009-09-24 Genentech Inc Behandlung von lfa-1 assozieerten krankheiten durch gesteigerte dosen von lfa-1 antagonist
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
EP1237575B1 (en) * 1999-12-14 2008-08-06 Genentech, Inc. Tnf-alpha antagonist and lfa-1 antagonist for treating rheumatoid arthritis
US7575921B2 (en) 1999-12-30 2009-08-18 Vbi Technologies, L.L.C. Spore-like cells and uses thereof
US7560275B2 (en) 1999-12-30 2009-07-14 Vbi Technologies, L.L.C. Compositions and methods for generating skin
AU2001230920A1 (en) * 2000-01-14 2001-07-24 Genentech Inc. Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1
EP1315812B1 (en) * 2000-09-01 2009-11-11 The Center for Blood Research, INC. Modified polypeptides stabilized in a desired conformation and methods for producing same
US20020151050A1 (en) 2000-10-30 2002-10-17 Vacanti Charles A. Isolation of spore-like cells from tissues exposed to extreme conditions
AU2003210802B2 (en) 2002-02-05 2009-09-10 Genentech Inc. Protein purification
US20060234226A1 (en) 2002-04-26 2006-10-19 Fahner Robert L Non-affinity purification of proteins
EP2085096A3 (en) 2002-09-11 2009-08-12 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
AU2004233346B2 (en) * 2003-04-23 2008-03-06 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)
CA2531595C (en) 2003-07-28 2015-12-08 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
CA2554965C (en) * 2004-02-19 2015-08-11 The Cbr Institute For Biomedical Research, Inc. Antibodies specific for activated conformation of lfa-1
EP3653641A1 (en) 2004-02-19 2020-05-20 Genentech, Inc. Cdr-repaired antibodies
BRPI0511305A (pt) * 2004-06-09 2007-12-04 Genentech Inc método de aliviar um granuloma anular ou sarcóide, artigo manufaturado e uso de um antagonista de lfa-1
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US20100267933A1 (en) 2006-12-21 2010-10-21 Moya Wilson Purification of proteins
EP2377527B1 (en) 2007-01-22 2013-07-17 Genentech, Inc. Polyelectrolyte precipitation and purification of antibodies
TR201802088T4 (tr) 2007-07-09 2018-03-21 Genentech Inc Polipeptidlerin rekombinan üretimi esnasında disülfür bağlarındaki indirgenmenin önlenmesi.
KR20140015166A (ko) 2007-10-30 2014-02-06 제넨테크, 인크. 양이온 교환 크로마토그래피에 의한 항체 정제
JP5770624B2 (ja) 2008-04-09 2015-08-26 ジェネンテック， インコーポレイテッド 免疫関連疾患の治療のための新規組成物と方法
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
EP2145901B1 (en) 2008-07-18 2012-11-14 Technische Universität Braunschweig Recombinant anti-MUC1 antibodies
WO2010019148A1 (en) 2008-08-14 2010-02-18 Genentech, Inc. Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
JP5705115B2 (ja) 2008-09-10 2015-04-22 ジェネンテック， インコーポレイテッド 蛋白質の酸化的分解の予防のための組成物および方法
DK2370561T3 (da) 2008-12-16 2019-10-21 Emd Millipore Corp Omrøringstankreaktor og fremgangsmåde
WO2010074702A1 (en) 2008-12-16 2010-07-01 Millipore Corporation Purification of proteins
ES2547712T3 (es) 2009-02-27 2015-10-08 Genentech, Inc. Métodos y composiciones para el marcado de proteínas
ES2793348T5 (en) 2009-08-11 2025-04-11 Hoffmann La Roche Production of proteins in glutamine-free cell culture media
US9428548B2 (en) 2009-09-01 2016-08-30 Genentech, Inc. Enhanced protein purification through a modified protein A elution
CA2780549C (en) 2009-11-12 2017-01-03 Vbi Technologies, L.L.C. Subpopulations of spore-like cells and uses thereof
US20120309056A1 (en) 2010-02-04 2012-12-06 Leon Arnaud Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
EP3513810A1 (en) 2010-03-22 2019-07-24 F. Hoffmann-La Roche AG Compositions and methods useful for stabilizing protein- containing formulations
WO2011139718A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods useful for reducing the viscosity of protein-containing formulations
DK2571903T3 (da) 2010-05-17 2019-11-04 Emd Millipore Corp Polymerer, der reagerer på stimuli, til oprensning af biomolekyler
RU2614125C2 (ru) 2010-05-28 2017-03-22 Дженентек, Инк. Снижение уровня лактата и увеличение продукции полипептида путем ингибирования экспрессии лактатдегидрогеназы и киназы пируватдегидрогеназы
JP5894154B2 (ja) 2010-06-24 2016-03-23 ジェネンテック， インコーポレイテッド タンパク質含有製剤の安定化のためのアルキルグリコシドを含む組成物及び方法
RU2013110844A (ru) 2010-08-13 2014-09-20 Дженентек, Инк. АНТИТЕЛА ПРОТИВ IL-1β И IL-18, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
WO2012088272A1 (en) * 2010-12-21 2012-06-28 Duke University Methods and compositions combining immunotherapy with monocyte activation
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
KR20210025692A (ko) 2011-12-22 2021-03-09 제넨테크, 인크. 이온 교환 막 크로마토그래피
CN104350156B (zh) 2012-03-27 2019-04-02 弗·哈夫曼-拉罗切有限公司 用于重组蛋白质的改进的收获操作
EP3427721B1 (en) 2012-05-18 2025-03-19 Genentech, Inc. High-concentration monoclonal antibody formulations
EP2934602B1 (en) 2012-12-19 2019-02-27 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
MY175896A (en) 2013-07-09 2020-07-14 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
KR20230118704A (ko) 2013-07-16 2023-08-11 제넨테크, 인크. Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을치료하는 방법
ES2825574T3 (es) 2014-07-09 2021-05-17 Hoffmann La Roche Ajuste del pH para mejorar la recuperación por descongelación de bancos de células
HUE070383T2 (hu) 2014-11-05 2025-06-28 Annexon Inc Humanizált C1Q anti-komplement faktor antitestek és alkalmazásaik
EP3344658B1 (en) 2015-09-02 2022-05-11 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
PT3353210T (pt) 2015-09-25 2025-01-10 Hoffmann La Roche Anticorpos anti-tigit e métodos de utilização
IL296130A (en) 2015-11-24 2022-11-01 Annexon Inc Anti-complement factor c1q fab fragments and uses thereof
EP3436610A1 (en) 2016-03-29 2019-02-06 Geltor, Inc. Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
CN110049778A (zh) 2016-12-22 2019-07-23 豪夫迈·罗氏有限公司 减少冻干多肽重构时间的方法和制剂
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
AU2019299358A1 (en) 2018-07-03 2021-02-18 Bristol-Myers Squibb Company Methods of producing recombinant proteins
CN113166695A (zh) 2018-10-10 2021-07-23 勃林格殷格翰国际公司 用于高密度生物反应器培养中的膜气体转移的方法
MX2021012032A (es) 2019-04-01 2021-11-03 Genentech Inc Composiciones y metodos para estabilizar formulaciones que contienen proteinas.
EP3953380A4 (en) 2019-04-12 2023-01-25 Geltor, Inc. RECOMBINATION ELASTIN AND ASSOCIATED PRODUCTION
US20220315887A1 (en) 2019-08-01 2022-10-06 Bristol-Myers Squibb Company Methods of improving protein productivity in fed-batch cell cultures
US20230357815A1 (en) 2020-09-22 2023-11-09 Bristol-Myers Squibb Company Methods for increasing productivity of therapeutic proteins
WO2023015234A1 (en) 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
WO2023049687A1 (en) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ236792A (en) * 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions
US6096871A (en) * 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life

Also Published As

Publication number Publication date
ES2221045T3 (es) 2004-12-16
EP1516629B1 (en) 2013-04-03
EP1516629A2 (en) 2005-03-23
IL130143A0 (en) 2000-06-01
DK1516629T3 (da) 2013-06-03
DE122004000047I2 (de) 2006-06-14
NL300163I2 (nl) 2005-07-01
DE69729209D1 (de) 2004-06-24
JP3778945B2 (ja) 2006-05-24
EP0941344B1 (en) 2004-05-19
EP0941344A1 (en) 1999-09-15
JP2001505425A (ja) 2001-04-24
DE69729209T2 (de) 2005-05-19
DE122004000047I1 (de) 2005-04-21
NL300163I1 (nl) 2005-01-03
FR04C0028I2 (cs) 2007-10-26
ATE267257T1 (de) 2004-06-15
AU731817C (en) 2001-11-01
AU731817B2 (en) 2001-04-05
FR04C0028I1 (cs) 2005-02-11
AU4992997A (en) 1998-06-22
PT941344E (pt) 2004-10-29
KR20000069147A (ko) 2000-11-25
JP2006036779A (ja) 2006-02-09
KR100532178B1 (ko) 2005-12-01
CA2272842C (en) 2012-05-15
JP4309383B2 (ja) 2009-08-05
LU91122I2 (fr) 2005-01-10
AR008919A1 (es) 2000-02-23
WO1998023761A1 (en) 1998-06-04
ZA979599B (en) 1999-04-28
IL130143A (en) 2006-08-01
IL175583A0 (en) 2006-09-05
EP1516629A3 (en) 2006-09-27
CA2272842A1 (en) 1998-06-04

Similar Documents

Publication Publication Date Title
DK0941344T3 (da) Humaniserede anti-CD11a-antistoffer
CY2005008I1 (el) Αντισωματα αντι - vegf
NO955167D0 (no) Monoklonalt anti-
DK0837927T3 (da) Anti-CD80-antistoffer
NO985464D0 (no) Konsentrert antistoffpreparat
DE69920897D1 (de) Monoklonale antikörper mit verringerter immunisierungsfähigkeit
DK145493D0 (da) Antistof
DE69622451D1 (de) Funktelefon
FI964845L (fi) CD44v6:n vastaiset monoklonaaliset vasta-aineet
FI951568A7 (fi) Immobilisoitu beta-mannaasi
DE69625078D1 (de) Analysator
DE69609663D1 (de) Automatische Analysevorrichtung
DE69738312D1 (de) Hepatitis b monoklonale antikörper
NO981454L (no) Anti-FAS-antistoffer
DE69624334D1 (de) Fixiervorrichtung
KR970025982U (ko) 콘센트
BR9609863A (pt) Fecho
DE69618534D1 (de) Fixiervorrichtung
KR960036248U (ko) 도마
BR9709080A (pt) Anticorpo monoclonal anti-MP52 humano
KR970003345U (ko) 콘센트
KR960035664U (ko) 콘센트
KR970018128U (ko) 토건용 축조부재
KR970020763U (ko) 도마
ITMI950511A0 (it) Fotodensitometro parallelo perfezionato